Jason Holligan MD, Moatamn Skuk MD, Wael Kanjo MD, Walter Agyeman MD, Elsie Kodjoe MD
{"title":"Association between apolipoprotein B and obesity: A cross-sectional analysis of NHANES data","authors":"Jason Holligan MD, Moatamn Skuk MD, Wael Kanjo MD, Walter Agyeman MD, Elsie Kodjoe MD","doi":"10.1016/j.jacl.2025.04.080","DOIUrl":null,"url":null,"abstract":"<div><h3>Background/Synopsis</h3><div>Apolipoprotein B (apoB) plays a critical role in the development of atherosclerosis, making it an essential biomarker for cardiovascular disease (CVD). Obesity, a significant global health concern affects 40.3% of adults in the United States of America (US) according to the Centers for Disease Control and Prevention (CDC). As rates of both obesity and CVD continue to rise globally, understanding the relationship between obesity and apoB levels is crucial for developing targeted strategies to reduce cardiovascular risks. Despite its importance, few studies have explored the effect of obesity on apoB levels in a large cohort of adults in the US.</div></div><div><h3>Objective/Purpose</h3><div>This study aims to investigate the association between obesity and apoB levels among US adults.</div></div><div><h3>Methods</h3><div>This cross-sectional study used data from the National Health and Nutrition Examination Survey (NHANES) 2009–2016. The sample included 10,539 adults aged 18 years and older who had apoB levels measured, representing approximately 62 million non-institutionalized US adults. Participants were classified as obese (BMI ≥ 30 kg/m²) or non-obese (BMI <30 kg/m²). Apo B was analyzed as a continuous variable. Linear regression was performed to assess the association between obesity and apoB levels, adjusting for potential confounders including age, sex, race, diabetes, hypertension, and socioeconomic status. Effect modification was examined by sex and age group (< 65 years vs. ≥ 65 years).</div></div><div><h3>Results</h3><div>Among the 10,539 participants, the mean age was 48 years, 51% were female, and 41% were White. The average apoB level was 90.5 mg/dL. Obese adults had higher apoB levels (94 mg/dL) compared to non-obese adults (88 mg/dL). A one-unit increase in obesity was associated with a statistically significant 6.91 mg/dL increase in apoB levels [Coefficient: 6.91; p < 0.001; 95% CI: 5.90, 7.95]. After adjusting for confounders, the association remained statistically significant [Coefficient: 6.66; p < 0.001; 95% CI: 5.52, 7.81]. There was no significant difference in the association by sex; however, the association was stronger among younger individuals compared to older adults.</div></div><div><h3>Conclusions</h3><div>Obesity is significantly associated with higher apoB levels, particularly in younger individuals. Addressing obesity as a key component of CVD prevention strategies may help reduce apoB levels and the associated cardiovascular risk.</div></div>","PeriodicalId":15392,"journal":{"name":"Journal of clinical lipidology","volume":"19 3","pages":"Page e59"},"PeriodicalIF":3.6000,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of clinical lipidology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1933287425001564","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0
Abstract
Background/Synopsis
Apolipoprotein B (apoB) plays a critical role in the development of atherosclerosis, making it an essential biomarker for cardiovascular disease (CVD). Obesity, a significant global health concern affects 40.3% of adults in the United States of America (US) according to the Centers for Disease Control and Prevention (CDC). As rates of both obesity and CVD continue to rise globally, understanding the relationship between obesity and apoB levels is crucial for developing targeted strategies to reduce cardiovascular risks. Despite its importance, few studies have explored the effect of obesity on apoB levels in a large cohort of adults in the US.
Objective/Purpose
This study aims to investigate the association between obesity and apoB levels among US adults.
Methods
This cross-sectional study used data from the National Health and Nutrition Examination Survey (NHANES) 2009–2016. The sample included 10,539 adults aged 18 years and older who had apoB levels measured, representing approximately 62 million non-institutionalized US adults. Participants were classified as obese (BMI ≥ 30 kg/m²) or non-obese (BMI <30 kg/m²). Apo B was analyzed as a continuous variable. Linear regression was performed to assess the association between obesity and apoB levels, adjusting for potential confounders including age, sex, race, diabetes, hypertension, and socioeconomic status. Effect modification was examined by sex and age group (< 65 years vs. ≥ 65 years).
Results
Among the 10,539 participants, the mean age was 48 years, 51% were female, and 41% were White. The average apoB level was 90.5 mg/dL. Obese adults had higher apoB levels (94 mg/dL) compared to non-obese adults (88 mg/dL). A one-unit increase in obesity was associated with a statistically significant 6.91 mg/dL increase in apoB levels [Coefficient: 6.91; p < 0.001; 95% CI: 5.90, 7.95]. After adjusting for confounders, the association remained statistically significant [Coefficient: 6.66; p < 0.001; 95% CI: 5.52, 7.81]. There was no significant difference in the association by sex; however, the association was stronger among younger individuals compared to older adults.
Conclusions
Obesity is significantly associated with higher apoB levels, particularly in younger individuals. Addressing obesity as a key component of CVD prevention strategies may help reduce apoB levels and the associated cardiovascular risk.
期刊介绍:
Because the scope of clinical lipidology is broad, the topics addressed by the Journal are equally diverse. Typical articles explore lipidology as it is practiced in the treatment setting, recent developments in pharmacological research, reports of treatment and trials, case studies, the impact of lifestyle modification, and similar academic material of interest to the practitioner.
Sections of Journal of clinical lipidology will address pioneering studies and the clinicians who conduct them, case studies, ethical standards and conduct, professional guidance such as ATP and NCEP, editorial commentary, letters from readers, National Lipid Association (NLA) news and upcoming event information, as well as abstracts from the NLA annual scientific sessions and the scientific forums held by its chapters, when appropriate.